8/4/2026

Samsung's Retail Investors Seek Extra Shareholder Meeting Over Buybacks, Bonuses

Reuters (08/04/26) Jin, Hyunjoo

South Korean retail shareholder platform ACT said on Tuesday it had launched a campaign to call an extraordinary shareholders' meeting at Samsung Electronics (005930.KS) urging the chipmaker to buy back about $32 billion worth of shares and set limits on performance bonuses. ACT said it would begin collecting electronic signatures from shareholders at 5 p.m. local time and seek support from the National Pension Service and domestic and overseas asset managers to meet the 3% ownership threshold required to call the meeting. The move comes after Samsung shares lost over one third of their value since hitting record-highs in June, despite the artificial intelligence boom. The falls were driven by a sharp wave of deleveraging and renewed skepticism regarding the durability of AI infrastructure spending. "This is not simply an expression of dissatisfaction over a falling share price. We are asking a basic capital-market question: who really owns a corporation?," it said in a statement, saying the campaign aims to help the company become a shareholder-friendly company. "Retail shareholders are like a company's fan club: they praise it when it performs well and take out the stick when it does not," it said. The proposed meeting could consider a proposal to approve a 45.5 trillion won ($31.79 billion) share buyback program, it said. A second proposal would seek to require shareholder approval for an upper limit on performance bonuses tied to company operating profit. In May, Samsung agreed to assign 10.5% of operating profit for special bonuses for chip division employees as part of a wage deal that averted a major strike. ACT said such bonuses could amount to hundreds of billions of dollars over a decade, and argued that rules governing payouts of that scale should not be set solely by the board. Samsung Electronics did not immediately respond to a request for comment.

Read the article

8/3/2026

KKR to Take Medical-Equipment Maker Integer Holdings Private in $5.7 Billion Deal

Reuters (08/03/26) Ananthan, Padmanabhan

KKR (KKR.N) will take medical-device manufacturer Integer Holdings (ITGR.N) private in an all-cash deal valued at about $5.7 billion, expanding its healthcare portfolio with the acquisition of a key supplier to the medtech industry. Shares of Plano, Texas-based Integer Holdings rose 2.6% in early trading. The private equity firm is gaining a critical supplier to medical-device companies, with Integer producing components and finished products used in cardiovascular and neuromodulation therapies, among other applications. The takeover comes amid sustained private-equity interest in healthcare. Some notable buyouts over the past year include American Industrial Partners' $1.27 billion acquisition of Avanos Medical and Blackstone (BX.N) and TPG's (TPG.O) deal for women's-health-focused diagnostics firm Hologic for $18.3 billion. KeyBanc Capital Markets analyst Brett Fishbin told Reuters the latest acquisition was positive for medtech as it showed private equity firms were "realizing the value of public companies with strong track records" despite "transitory headwinds" that have weighed on stock prices, citing Integer as an example. Fishbin said Integer could serve as a platform for KKR, which could "acquire additional smaller assets" and layer them into the company's existing operations. For KKR, which had $796 billion in assets under management at the end of the second quarter, the buyout will deepen its healthcare exposure and rank among its largest deals in the sector since its $9.9 billion take-private of Envision Healthcare in 2018. Under the deal terms announced on Monday, KKR is paying $127 per share in cash, representing a 4.78% premium to Integer's closing price on Friday. The transaction includes the assumption of Integer's outstanding debt. Integer has faced investor pressure in the past. In March, the company reached an agreement with Irenic Capital Management, one of its largest shareholders, to appoint two directors to its board. Irenic owns a stake of more than 3% in Integer, according to LSEG data. The deal with KKR is expected to close by the end of the year, Integer Holdings said.

Read the article

8/3/2026

Neuronetics Reaches Accord With Jorey Chernett After Sale Pressure

Philadelphia Business Journal (08/03/26) George, John

Neuronetics Inc. (NASDAQ: STIM) said Monday it has found a way to align and work with a major shareholder who just four months ago urged the company to consider selling part of its core business. Jorey Chernett in April criticized the Malvern medical device developer for "chronically underperforming" since it acquired clinic operator Greenbrook TMS Inc. in December 2024. Neuronetics said the understanding with Chernett announced Monday confirms its board’s commitment to maximizing shareholder value. The board, the company said, will continue to regularly evaluate strategic, operational and financial opportunities. It made no commitment to selling any part of the business. “We appreciate the constructive engagement we’ve had with Mr. Chernett, and we’re aligned on the importance of delivering long-term shareholder value as a priority,” said Dan Reuvers, who took over as CEO of Neuronetics in March, in a statement. Chernett will have an opportunity to recommend a newly appointed member of the board. The appointment, Neuronetics said, would be "designed to augment direct shareholder participation in the company's chosen strategy" that combines treatment technologies with direct patient care. Neuronetics' stock was up nearly 11% Monday to $2.20 in afternoon trading. Chernett argued in April that Neuronetics "as a micro-cap company with finite capital and limited management bandwidth cannot adequately serve two distinct businesses simultaneously." He wanted the company to keep the clinic business and sell its transcranial magnetic stimulation, or TMS, device businesses. The entrepreneur and managing member of the Pointillist Family Office in Michigan owns 14.12% of the company's outstanding shares. Chernett is the company's second largest shareholder. Founded in 2003, Neuronetics is the developer of the NeuroStar TMS Therapy System, which uses magnetic pulses to stimulate specific areas of the brain to treat depression. It acquired Greenbrook TMS Inc., a Toronto-based company that operates a U.S. network of 95 clinics focused on TMS therapy, for about $45 million in stock in 2024. The deal positioned Neuronetics as both the maker of the NeuroStar system and an operator of clinics that deliver TMS therapy. Neuronetics said its largest shareholder, Madryn Asset Management, also reaffirmed its conviction in the long-term prospects of the business. Madryn owns about 30% of the company's outstanding shares. In 2025, Neuronetics' revenue nearly doubled to $149.2 million as a result of the Greenbrook acquisition. The company narrowed its net loss to $39.1 million in 2025 from $43.7 million in 2024.

Read the article

7/30/2026

LSEG Narrows Revenue Forecast, says It Had 'Constructive' Dialogue with Elliott

Reuters (07/30/26) Aripaka, Pushkala

London Stock Exchange Group (LSEG.L) narrowed its full-year revenue growth forecast and slightly exceeded first-half sales forecasts on Thursday, although its shares slipped amid some disappointment among analysts. LSEG is facing pressure from activist investor Elliott Management, which bought a stake in the London Stock Exchange operator and has been pushing for portfolio changes and margin improvements, as well as broader investor concerns that AI could disrupt its financial data business and squeeze margins. LSEG CEO David Schwimmer said on Thursday there had been "good, constructive dialogue with Elliott", without elaborating. Shares in LSEG, which have risen 21% since Elliott's stake became public on February 11, fell 3.1% following the results. LSEG's share price is now flat for the year, compared to a 10% rise for the FTSE 100. "The market will have the reaction that the market will have," said Schwimmer. "But we feel very good about our opportunity set and we have upped our guidance and tightened our guidance range for the second half of this year with both revenue and margin, which is a reflection of that confidence," he added. LSEG had previously forecast organic constant-currency growth in total income, excluding recoveries, at the upper end of a 6.5% to 7.5% range. Its new 7.0% to 7.5% range remains below analyst expectations of 7.8% growth for the year. "Guidance may disappoint," said Citigroup analyst Andrew Lowe, adding the revenue mix was "likely to be viewed as modestly negative". The Iran war prompted a spike in trading activity across all major asset classes, helping LSEG's markets business, which typically benefits from such volatility. For the six months to June, total income excluding recoveries rose 8.4% versus expectations of 8.3%. Its markets business delivered 11.9% growth in the first half. LSEG's push to address investor concerns about AI comes as the data provider seeks to reassure shareholders. "We're always evaluating our business, and if there's anything that it makes sense to consider, that is something that we're always thinking through," Schwimmer told reporters. LSEG has been investing in its analytics business and partnering with AI firms including OpenAI and Anthropic to roll out AI tools and license its data. Its data and analytics business reported a 5.1% rise in organic growth in the second quarter. "12 months on from when AI concerns first impacted LSEG shares, the continued improvement in financials should help to reassure the market that the vulnerabilities have been overblown," said RBC analyst Ben Bathurst in a note. LSEG forecast EBITDA (earnings before interest, tax, depreciation and amortisation) margin growth of around 100 basis points, versus its previous expectation of an 80 to 100 bp rise. It also said it planned a further £1.35 billion ($1.8 billion) share buyback, to be completed by February next year, and raised its dividend by 17%.

Read the article

7/30/2026

Jana Pushes Fiserv to Review Entire Portfolio, Refresh Board

Reuters (07/30/26) Herbst-Bayliss, Svea

Jana Partners is ratcheting up pressure on payments company Fiserv (FISV.O), pushing it to launch a formal review of its entire portfolio rather than sell assets piecemeal, according to a letter seen by Reuters on Thursday. The New York-based hedge fund, which has been invested in Fiserv since late 2025, praised the company for reportedly considering a sale of its debit network assets. But in a letter to the board and new CEO, Jana's managing partner and portfolio manager Scott Ostfeld said it now wants management to go further and review the entire portfolio, arguing that asset sales could restore credibility with investors and boost the stock price. Jana also reiterated its position that Fiserv needs new directors to address governance issues. After months of private negotiations with Milwaukee-headquartered Fiserv, Jana is becoming more vocal, having first discussed its hopes for the company publicly in early June and now following up with the more pointed letter to the company. Fiserv has a market value of nearly $30 billion but has lost more than half of its value in the last 12 months with its stock price closing at $55.63 on Wednesday. The announcement last month by CEO Mike Lyons, who had been in the top job for only a year, that he was leaving to run Truist Financial Corporation (TFC.N), added to the stock's decline. In the letter, Jana blamed management turnover and unspecified and ongoing missteps for making investors skittish. It singled out the board for failing to attract and keep talented top executives and said new blood was needed in the boardroom to fix these problems. Most critical, however, was the need to publicly announce a comprehensive review, the letter said. In July, the Wall Street Journal reported that big banks, including JPMorgan Chase (JPM.N) and Bank of America (BAC.N), held preliminary and tentative discussions to possibly buy Fiserv's debit network assets. No deal has been announced. Fiserv announced smaller efforts earlier this year including partnering with Bridgeport Partners to form a joint venture spinning off its ATM managed services, cash logistics and MoneyPass networks. And it sold its Education Solutions student loan servicing business to Infinite Computer Solutions. Jana, which has experience in pushing financial sector companies to perform better, previously said it believes Fiserv can help banks and credit unions adopt artificial intelligence tools in their own businesses, including through a recently announced collaboration with OpenAI. Three years ago, Jana successfully pushed Fiserv competitor Fidelity National Information Services (FIS.N) to separate its Worldpay payments business. The hedge fund is currently pushing for a big share buyback and breakup at holding company Markel Group and a sale of digital banking platform Alkami Technology (ALKT.O).

Read the article

7/30/2026

Seacor Is Reviewing Alternatives After Shareholders Called for Sale

Maritime Executive (07/30/26)

Weeks after two of the company’s largest shareholders called for the immediate sale to maximize value, Seacor Marine (NYSE: SMHI) confirmed it has retained advisers and launched a “strategic alternatives review.” The news that the company is looking at options, including a sale of its fleet, assets, merger, or sale of the company, came after it reported improved utilization and day rates, but a decrease in revenues and direct vessel profit during the most recent quarter. Seacor, which provides services to the offshore sector, including oil, gas, and wind farms, highlighted that its utilization improved following the repositioning of vessels. It also emphasized that it “remains constructive of opportunities across several of our international markets.” The Middle East conflict, however, is impacting the company as it reports increased labor and insurance costs and a general softening in offshore activity, while it has six vessels active in the region, and two in maintenance. It said it continues to work for customers in Saudi Arabia and Qatar, but also said its two premium liftboats in the region are not expected to operate in the coming quarter. Seacor reported progress off its lows in the first quarter, but still had a 10% decline in year-over-year revenues and a four basis point decline in vessel profit year-over-year. This quarter's results also included the completion of the sale of five vessels and other equipment. It provided a recognized gain of $31.3 million. “Over the past several years, the Company has worked diligently to optimize its fleet, strengthen its balance sheet, and position Seacor Marine to benefit from improving offshore market fundamentals,” said Andrew R. Morse, Non-Executive Chairman of the Board. However, the company also confirmed that it has launched a review process aimed at determining the best course to maximize value for shareholders. This came after shareholder Pointillist Family Office, which owns more than 7% of the stock and is the largest holder, demanded in June that the board begin a strategic review to sell the company or the fleet. Bloomberg reported that Jorey Chernett, CEO of the investment fund, said the company's fleet was worth more than $1 billion and advocated for accelerating sales or selling the company. Days later, Yoav Saffar, founder of Smarlenses Capital, which holds 3.5% of the stock, released a letter his group had sent to Seacor entitled “The Time has Come.” In it, he argues that competitors used the market downturn to restructure and emerged deleveraged, while Seacor maintained its fleet and continued to carry a substantially heavier debt burden. Noting the strong market rebound, Saffar called Seacor's current share price “woefully below the intrinsic value of its fleet and other assets.” He said the valuation gap has remained as the market recovered and management urged patience. He concluded Seacor “never had the scale required” for its strategy to succeed. Furthermore, he concluded after analyzing the value of the assets that the board needed to initiate a process to realize the embedded value. He said the shareholders “have been waiting long enough, and the time has come.” The share price jumped more than 23% on Thursday, July 30, after the board confirmed it had launched the process. It said there are no assurances, saying it could range from the outright sale of the company to assets, a merger, a business combination, or other transactions. The stock is now at $9.54, while Saffar noted that Clarkson had set a $22 figure in June for the intrinsic value. The door has been opened for further consolidation in an industry that has seen a host of mergers and major transactions in the past few years.

Read the article

7/29/2026

Invisalign Maker Strikes Settlement Deal With Elliott Investment Management

Bloomberg (07/29/26) Sun, Mengqi; Baker, Liana

Align Technology Inc. (NASDAQ: ALGN), the maker of Invisalign teeth-straightening products, said it has agreed to add three new directors to its board as part of a settlement with hedge fund Elliott Investment Management. Elliott had built a significant stake in Align that made it one of the dental device company’s largest investors, Bloomberg News reported in March. Align said the decision follows discussions with Elliott about its board refreshment and governance. The board is also starting what it calls a comprehensive “strategic and operating model review” to support the company’s next phase of growth. In addition, it will increase its buyback commitment this year to shares worth $400 million to $500 million. “We appreciate the constructive dialogue with Elliott as we continue to advance Align’s strategic priorities,” Align Chairman Kevin Conroy said in a statement. Align hasn’t identified the three board candidates but said it will search for “highly qualified leaders with significant experience in healthcare technology, medical devices, global operations, consumer technology, innovation and scaling of high-growth businesses.” Elliott Partner Marc Steinberg said the board changes and other actions are important steps, adding that his firm is one of the company’s largest shareholders because it believes in its long-term growth opportunities. Shares of Align, which have gained 15% this year, rose 2.6% to $180.08 in New York trading Wednesday, giving the company a market value of about $12.9 billion. After the close of trading, Align reported a 4.3% year-over-year increase in revenue for the quarter ended on June 30, but a 13% drop in net income for the period. Align’s stock has cratered after peaking at $729.92 in 2021 amid a boom in spending on cosmetic procedures like teeth straightening, thanks in part to consumers seeing how they looked on videoconferencing platforms during the Coronavirus pandemic. Use of the company's products has decreased since then. Align, founded in 1997 and based in Tempe, Arizona, makes clear aligners that take the place of traditional metal braces. Its products have been used by more than 22 million people, according to its website. Elliott has invested in healthcare companies including Charles River Laboratories International Inc. (NYSE: CRL), which last year announced a cooperation agreement with the investor that included a plan to refresh its board. Elliott also built a stake in biotech company Bio-Rad Laboratories Inc. (NYSE: BIO), planning to help it explore ways to improve its stock price, Bloomberg News reported in May.

Read the article